A Study to Test the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of MK1006 (MK-1006-002)(COMPLETED)

• Status: Completed
• Trial end date: 2008-12-01
• Target enrollment: 0
• Participant gender: All

Summary

This study will assess the safety, tolerability, pharmacokinetics, and pharmacodynamics of single doses of MK1006

• Phase: Phase 1
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Merck Sharp & Dohme Corp.

Criteria

Inclusion Criteria:

• Participant is between 18 and 55 years of age. Participants up to 65 years of age may be enrolled in Panels B and C

• Female participants must be postmenopausal or otherwise unable to have children

• Participant has a body mass index (BMI) less than or equal to 42 kg/m^2 at the screening visit

• Participant has type 2 diabetes and is being treated with either diet and exercise or a single oral anti-hyperglycemic medication. For Panels B and C, participant may be treated with combination oral anti-hyperglycemic medications

• Participant is willing to follow the American Heart Association (AHA) diet and exercise program throughout the study

• Participant is a nonsmoker or has not used nicotine-containing products for 6 months prior to study start

Exclusion Criteria:

• Participant has a history of stroke, seizures, or other neurological disorders

• Participant has a recent history of eye infection or other inflammatory eye conditions

• Participant has glaucoma or is blind

• Participant has had eye surgery within 6 months of study start (Lasik is permitted)

• Participant has type 1 diabetes

• Participant cannot stop taking any of their current prescription or non-prescription medications during the study

• Participant consumes more than 3 alcoholic beverages per day

• Participant consumes more than 6 caffeinated beverages per day

• Participant has had major surgery or has donated blood within 4 weeks of study start

• Participant has multiple and/or severe allergies to drugs or food